Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003
Authors
Clarke, Noel WAli, Adnan
Ingleby, FC
Hoyle, Alex P
Amos, CL
Attard, G
Brawley, CD
Calvert, J
Chowdhury, S
Cook, A
Cross, W
Dearnaley, D
Douis, H
Gilbert, D
Gillessen, Silke
Jones, RJ
Langley, RE
MacNair, A
Malik, Z
Mason, MD
Matheson, D
Millman, R
Parker, CC
Ritchie, AWS
Rush, H
Russell, JM
Brown, J
Beesley, S
Birtle, A
Capaldi, L
Gale, J
Gibbs, S
Lydon, A
Nikapota, A
Omlin, A
O'Sullivan, JM
Parikh, O
Protheroe, A
Rudman, S
Srihari, NN
Simms, M
Tanguay, JS
Tolan, S
Wagstaff, J
Wallace, J
Wylie, James P
Zarkar, A
Sydes, MR
Parmar, MKB
James, ND
Affiliation
Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, ManchesterIssue Date
2020
Metadata
Show full item recordAbstract
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. [Ann Oncol. 2019]Citation
Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. Ann Oncol. 2020;31:442.Journal
Annals of OncologyDOI
10.1016/j.annonc.2020.01.002PubMed ID
32067690Additional Links
https://dx.doi.org/10.1016/j.annonc.2020.01.002Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2020.01.002
Scopus Count
Collections
Related articles
- [Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial].
- Authors: von Amsberg G
- Issue date: 2020 Jun
- Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.
- Authors: van Soest RJ, de Wit R
- Issue date: 2015 Dec 22
- Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
- Authors: Damodaran S, Lang JM, Jarrard DF
- Issue date: 2019 May
- Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
- Authors: Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, Scagliotti GV, Di Maio M
- Issue date: 2016 Apr
- Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
- Authors: James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MKB, Ritchie AWS, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR
- Issue date: 2015 Jun